Treatment of t-helper cell type 2 mediated immune diseases

Details Treatment of t-helper cell type 2 mediated immune diseases Treatment of t-helper cell type 2 mediated immune diseases

A - Human Necessities

61

K

A61K 31/38 (2006.01) A61K 31/19 (2006.01) A61K 31/192 (2006.01) A61K 31/195 (2006.01) A61K 31/20 (2006.01) A61K 31/35 (2006.01) A61K 31/352 (2006.01) A61K 31/382 (2006.01) A61K 31/385 (2006.01) A61K 31/415 (2006.01) A61K 31/4184 (2006.01) A61K 31/44 (2006.01) A61K 31/4439 (2006.01) A61K 31/55 (2006.01) A61K 31/551 (2006.01)

Patent

CA 2307879

Retinoids with retinoid receptor antagonistic activity called retinoid antagonists, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found to be efficacious in the treatment of T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

L'invention concerne des rétinoïdes présentant une activité antagoniste du récepteur rétinoïde, appelés antagonistes de rétinoïde, leurs sels pharmaceutiquement acceptables et leurs esters hydrolysables et pharmaceutiquement acceptables, dont on a découvert l'efficacité dans le traitement des maladies immunes induites par les lymphocytes T auxiliaires de type 2 (Th2), telles que les maladies allergiques induites par l'immunoglobuline E (IgE).

Affiliated with

Also associated with

Rating

Treatment of t-helper cell type 2 mediated immune diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of t-helper cell type 2 mediated immune diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of t-helper cell type 2 mediated immune diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1355025